Entry Point Capital, LLC Keros Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
A detailed history of Entry Point Capital, LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 11,535 shares of KROS stock, worth $117,656. This represents 0.08% of its overall portfolio holdings.
Number of Shares
11,535Holding current value
$117,656% of portfolio
0.08%Shares
2 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.8MCall Options Held
62.7KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$25.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.96MShares$20 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$19.4 Million0.19% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$15.5 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$15.4 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $263M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...